EGFR and lung carcinoma: For instance, initial studies with R26-A3B in an EGFR-driven lung cancer model indicate that A3B is capable of fueling tumor evolution and contributing to drug resistance (even in the absence of inflicting overt APOBEC3 signature mutations).58